CVS Health Corporation (CVS) Updates its Commercial Formularies

​CVS Health Corporation (NYSE:CVS) is one of the Best Undervalued Stocks to Buy Under $100. On May 5, the company announced that its pharmacy benefit arm is updating its commercial formularies effective July 1, 2026. This shift is aimed at lower-cost biosimilars over brand-name reference drugs.

​Management noted that the most prominent change includes replacing Stelara with two FDA-approved interchangeable biosimilars called Pyzchiva and Yesintek. As per the new arrangement, most members are expected to pay nothing out-of-pocket. The release highlighted that the expansion extends beyond Stelara into specialty categories, including multiple sclerosis and rare blood disorders.

​Moreover, the biosimilar alternatives to Tysabri and Soliris are also expected to gain preferred formulary status, thereby broadening affordable access across more conditions. CVS Health Corporation (NYSE:CVS) emphasized that all included biosimilars meet the same FDA standards for safety, effectiveness, and quality as their branded counterparts. These changes are based on three major priorities, including affordability, access, and long-term value for health plan sponsors and their members.

​In separate news, recently, on May 8, Wells Fargo analyst Stephen Baxter raised the firm’s price target on the stock from $102 to $103, while maintaining an Overweight rating on the shares. The rating is based on the company’s Q1 2026 results, which topped estimates. CVS Health Corporation (NYSE:CVS) posted $100.43 billion in revenue, reflecting 6.17% year-over-year increase and surpassing expectations by $5.14 billion. Moreover, the GAAP EPS of $2.30 also topped expectations by $0.37.

​CVS Health Corporation (NYSE:CVS) operates as a health solutions company.

While we acknowledge the risk and potential of CVS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CVS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Stocks to Buy While the Market Is Down and 14 Stocks That Will Double in the Next 5 Years. 

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.